SBIR Phase I: Targeted Delivery of siRNA using Engineered Toxin Bodies
National Science Foundation
Agency Tracking Number:
Solicitation Topic Code:
Small Business Information
111 W. Cooperative Way, Suite 201, Georgetown, TX, 78626-8201
Socially and Economically Disadvantaged:
AbstractThis Small Business Innovation Research (SBIR) Phase I project will demonstrate targeted delivery of small interfering RNA (siRNA) to HER2 overexpressing tumor cells using a unique Shiga-like toxin 1A (SLT1A) scaffold. Molecular Templates has developed a SLT1A library of variants containing a unique 12 amino acid insert, allowing each SLT1A variant unique binding characteristics. SLT1A toxin intrinsically facilitates endocytosis and intracellular routing into the cytosol. This proposed work will demonstrate targeted intracellular delivery of siRNA to HER2 overexpressing breast cancer cells using proprietary HER2-specific SLT1A variants. This work will enable the development of a platform technology that can selectively bind to diseased cells, force cellular uptake of the siRNA-toxin construct, and ensure proper intracellular routing of the siRNA into the cytosol for maximal therapeutic benefit. The broader/commercial impacts of this research will be to provide a novel drug delivery technology that could lead to new therapeutics for a variety of human diseases. As siRNA therapy is being pursued for various genetic, viral, and cancerous diseases, technologies to selectively deliver siRNA to diseased tissue are needed. Current innovations in siRNA delivery are focused on selective binding to diseased cells using nanoparticles conjugated to antibodies, aptamers, or peptides. However, these ligand-targeted approaches often poorly facilitate endocytosis, endosomal escape, and/or cytosolic delivery of siRNA. Thus, the intrinsic characteristics of our SLT1A variant library to accomplish proper intracellular delivery of siRNA along with selective binding to diseased cells of interest would help overcome a significant problem in delivery of siRNA therapeutics.
* information listed above is at the time of submission.